Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation
Fat tissue triggers inflammation in atrial fibrillation through a druggable pathway; existing diabetes drugs reversed abnormal heart rhythms in mice.
Kynurenic acid secreted by epicardial adipose tissue in AF patients was found to impair atrial lymphangiogenesis via GPR35, with lymphatic vessel density decreased in human AF specimens compared to sinus rhythm controls. Therapeutic lymphangiogenesis via VEGFC or a GLP-1/GIP/glucagon triple agonist (LY3437943) significantly reduced AF inducibility in mouse models, revealing a novel pathogenic pathway with pharmacologically actionable targets.
What the study was
- Study design
- Translational: human tissue analysis + in vitro organotypic culture + in vivo mouse models
- Population
- Human left atrial appendage specimens (AF patients vs. sinus rhythm)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nat Commun
Why it surfaced
Nat Commun study establishing a novel lymphatic dysfunction pathway in AF, with GLP-1 triple agonist as a therapeutic intervention. Extends GLP-1 biology into AF prevention. Preclinical mouse models limit score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.